Fresh analysis indicates that people who discontinue new slimming jabs like Wegovy and Mounjaro may regain reduced body mass far faster than those who stop traditional lifestyle plans.
Published data in a major health publication demonstrates that while obese people can lose substantial amounts of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using such drugs should be cognizant of the danger of fast weight regain when the treatment concludes," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting mass within about one and a half years.
Analyzing Treatments
The analysis, which examined dozens of studies involving thousands of participants, compared the results of the injectable medications with older methods.
Scientists point out that people who shed pounds through diet and exercise typically see a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Nutrition scientists believe the mode of action of the injections is key to understanding the amplified regain.
The injections imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Disease?
The NHS recommend the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the high risk of relapse, the therapy might need to be life-long.
This opinion is supported by drug manufacturers, who state that the results "emphasize the persistent character of obesity," comparing it to managing diseases like diabetes.
User Testimonies
Individuals who have discontinued the medication explain a powerful return of appetite.
"I experienced a switch flipping and you become starving," described one woman.
The struggle is compounded if users have not adopted sustainable dietary or behavioural modifications during therapy.
Widespread Use
Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is more common among females than males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and long-term success relies on combined behavioural changes.